C4X Discovery Signs a Neurodegeneration Drug Discovery Agreement with PhoreMost for Parkinson’s Disease

 C4X Discovery Signs a Neurodegeneration Drug Discovery Agreement with PhoreMost for Parkinson’s Disease

C4X Discovery Signs a Neurodegeneration Drug Discovery Agreement with PhoreMost for Parkinson’s Disease

Shots:

  • The agreement collaborates C4XD’s Taxonomy3 (target identification platform) with PhoreMost’s SITESEEKER (screening platform) to accelerate drug discovery initially focusing on Parkinson’s disease with expected profit sharing by both the companies on validated targets
  • The focus of the agreement is to advance C4XD drug discovery pipeline by validating targets identified by C4XD’s Taxonomy3 with the addition of PhoreMost’s SITESEEKER and provides chemical starting points to launch drug discovery programmes
  • Taxonomy3 is a novel in silico platform technology utilizing mathematical algorithms to identify drug targets.  SITESEEKER is based on PROTEINi’ technology providing 3D biological shape of natural protein fragment libraries

Click here to read full press release/ article | Ref: C4XD | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post